The future of weight loss is fast approaching. At a recent scientific conference, drug companies showed off a variety of next-generation drugs for both obesity and type 2 diabetes. Some of these treatments might help people lose even more weight than current forerunners like Novo Nordisk’s semaglutide—the active…
It’s hard to go a day without hearing something new about the latest diabetes and obesity medications, semaglutide and tirzepatide. Usually, the buzz is positive, but there has been a persistent claim made about these drugs that would make any potential user wary: They don’t only help you lose weight—they supposedly…
The millennial-skewed telehealth platform Hims & Hers announced Monday that is now offering customers a compounded version of semaglutide, the active ingredient in popular weight loss drugs like Ozempic and Wegovy.
The newest weight loss drug on the market, Zepbound, might also help keep people’s snoring down.
Pharmaceutical company Eli Lilly is making a plea to some of its customers: stop hoarding our weight loss drugs. In a new Oscar-themed commercial set to run on TV this weekend, the drugmaker is not-so-subtly telling people to stay away from its new blockbuster medications if they’re only looking to lose a few pounds.…
Another week, another study finding that Ozempic/Wegovy and similar drugs may do a lot more than just help people lose weight. New research has found that patients who start taking GLP-1 drugs are less likely to be diagnosed with depression and anxiety afterward, compared to similar patients not on the drug. The…
The newest obesity drug on the market, Eli Lilly’s tirzepatide, may also help keep people’s blood pressure in check, new research out Monday has shown. The study looked at clinical trial participants and found that people taking it experienced a drop in their systolic blood pressure on average compared to a placebo…
A popular class of weight loss drugs may offer more lasting success than assumed, new data from Epic Research suggests. The study of medical records found that a slight majority of people who took GLP-1 drugs like semaglutide either maintained or improved their weight loss in the year after they stopped using the…
A popular class of weight loss and diabetes drugs looks to be safer than feared, at least so far. This week, the Food and Drug Administration announced it hasn’t found compelling evidence that Wegovy, Ozempic, and other GLP-1 drugs can cause suicidal thoughts or behaviors—a concern that first emerged last year. The…
